TravelWifi Continues Global Growth, Acquires Barcelona-based Wifivox
11.11.2020 15:05:00 EET | Business Wire | Press release
TravelWifi CEO Wallace Davis announced today the recent acquisition of Barcelona-based Wifivox, the leading provider of mobile Wi-Fi solutions in Spain.
Founded in 2013, Wifivox has offices in Barcelona and Madrid. The company offers rentable Wi-Fi hotspot devices that can be ordered online and then picked up or dropped off at major airports and approximately 2,000 locations throughout Spain. Wifivox has a collaborative agreement with the official Barcelona tourism board and maintains more than 830 B2B partnerships in sectors ranging from events and media production companies to travel agencies and the hospitality industry.
“Few companies in our space have such an enviable reputation for quality and service,” says TravelWifi CEO Wallace Davis. “Having Wifivox join us, further strengthens our goal to become a global leader in mobile Wi-Fi solutions.” Davis also announced that Wifivox CEO and founder Borja Ruiz will remain with the company. “I am looking forward to helping the company expand its footprint across the world,” says Ruiz. “We believe that the Spanish market offers significant opportunities for TravelWifi.”
Wifivox joins TravelWifi in offering portable Wi-Fi solutions for rent or purchase to a global market. The pocket-size devices provide unlimited data at affordable prices, allowing people to stay connected as they travel, work remotely, or even attend virtual classes for school. TravelWifi also offers SIM card solutions, as well as a growing suite of mobile business products such as routers using virtual SIM technology to provide reliable backups to primary physical internet connectivity. Wifivox is the company’s seventh acquisition, joining:
- TEP – Focused on U.S. travelers
- Trinus – Unique SIM card offerings for Latin American B2B
- Yogofi – Hospitality-centric B2C rentals and B2B2C capacity throughout Asia
- Bienvenue – Service-oriented B2B2C offerings for the travel and hospitality industries
- Travelwifi – Paris-based B2C offerings with highly visible airport and event partnerships
- Wifi Republic – A leading provider of mobile Wi-Fi solutions in Indonesia
Previously known as DHI Telecom, the Houston-based parent company rebranded itself as TravelWifi in June. “We examined how we want the world to know us,” says Davis. “The TravelWifi name encapsulates our mission and resonates with our audiences. TravelWifi offers the ability to travel simply, with innovative solutions and connection to what matters. It is the next dimension of travel. Today.”
TravelWifi uses innovative virtual SIM technology to offer a suite of products focused on Wi-Fi connectivity and managed network solutions in more than 130 countries. Customers include business and leisure travelers, organizations dependent on mobile connectivity, as well as tens of thousands of members of the U.S. military and Department of Defense overseas. Its pocket-sized flagship product – the award-winning Sapphire Wi-Fi device – uses CloudSIM technology to create a hotspot with up to 4G LTE speeds. Recent recognition includes:
- Best Military Telecommunications Providers and Most Innovative Travel Gadget by Corporate Vision Telecom Awards, 2019
- Gold in Telecommunications for Sapphire by the Golden Bridge Awards, 2019
- Named Next-Gen Wi-Fi Solution of the Year by Mobile Breakthrough Awards, 2019
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201111005163/en/
Contact information
Debbie M. Edwards
VP of Marketing and Professional Services
1.323.599.1678 | debbie.edwards@travelwifi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom